文献速递肝病消化道肿瘤与早癌消化道出血

肝癌患者的门静脉高压与静脉曲张出血:预防和管理的证据缺口

Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management.
PubMed 文献 · Hepatology · 2023-01-13

本文综述肝癌合并门静脉高压(PHT)及急性静脉曲张出血的筛查、一级预防和管理策略。作者认为Baveno VII标准不适用于排除肝癌患者的高危食管静脉曲张(EV),除肝硬度测量(LSM)≥25 kPa者可直接用非选择性β受体阻滞剂(NSBBs)免内镜外,其余应行内镜;并支持NSBBs用于EV不论大小及胃静脉曲张的一级预防。

要点

  • 肝癌患者中Baveno标准不适用于排除高危食管静脉曲张。
  • LSM≥25 kPa的肝癌患者可直接用NSBBs而无需内镜。
  • 支持NSBBs用于EV不论大小及胃静脉曲张的一级预防。

核心结论

  • 恰当评估和治疗门静脉高压仍是改善肝癌患者预后的主要问题,许多问题尚无答案,为研究提供了广阔领域。

研究设计与样本

  • 本文为综述,讨论肝癌患者门静脉高压筛查、一级预防及急性静脉曲张出血管理的最佳策略。

主要发现

  • 肝癌治疗进展尤其是免疫治疗的出现明显改善了患者生存。
  • 预防肝硬化相关并发症如门静脉高压和急性静脉曲张出血已成为肝癌管理的一部分。
  • Baveno VII会议近期重新定义了肝硬化患者的筛查和预防,但关于这些标准在肝癌患者中适用性的数据稀少。

关键数值与推荐

  • 作者认为Baveno标准不适用于排除肝癌患者的高危食管静脉曲张。
  • 作者认为除LSM≥25 kPa的肝癌患者可直接接受NSBBs而不行内镜外,其余肝癌患者应行内镜。
  • 作者支持NSBBs作为EV不论大小及胃静脉曲张的一级预防,因这些患者存在临床显著门静脉高压。

临床怎么用

  • 作者认为Baveno标准不适用于排除肝癌患者的高危食管静脉曲张,应行内镜。
  • 作者认为LSM≥25 kPa的肝癌患者可直接接受NSBBs而不行内镜。
  • 作者支持NSBBs用于EV不论大小及胃静脉曲张的一级预防。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Portal hypertension (PHT) and HCC are 2 major complications of cirrhosis that often coexist in the same patient and impact the prognosis, especially in patients with acute variceal bleeding. In this review, we aim to discuss the best strategy for PHT screening and primary prophylaxis, as well as the management of acute variceal bleeding, to improve the management of PHT in HCC patients. RESULTS: Recent therapeutic advances observed in the management of HCC, notably through the advent of immunotherapy, have led to a clear improvement in the survival of patients. The prevention of complications related to underlying cirrhosis, such as PHT and acute variceal bleeding, is now part of the management of HCC patients. The Baveno VII conference recently redefined screening and prophylaxis in patients with cirrhosis. However, data regarding the applicability of these criteria in patients with HCC have been sparse. From our point of view, the Baveno criteria are not appropriate to exclude high-risk esophageal varices (EV) in HCC patients, and endoscopy should be performed except in HCC patients with a liver stiffness measurement (LSM) ≥25 kPa, who should benefit from nonselective beta-blockers (NSSBs) without performing endoscopy. We are also in favor of using NSBBs as primary prophylaxis in patients with EV regardless of the size and with gastric varices since these patients display clinically significant PHT. CONCLUSIONS: Appropriate evaluation and treatment of PHT remain major issues in improving the outcomes of HCC patients. Many questions remain unanswered, opening the field to many areas of research.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Allaire M, Thabut D. Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management. Hepatology. 2023. PMID: 36631021. doi:10.1097/HEP.0000000000000291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。